1
Clinical Trials associated with Dendritic Killer Cell (DKC)(FullHope Biomedical)Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC. The primary endpoint of safety evaluation includes physical examination, assessment of vital sign, laboratory test, concomitant medication, and adverse event (AE). The secondary endpoints regarding efficacy includes the generation of tumor specific immune response by detecting CD3+ CD8+ CD69+ IFN-gamma+ T cells, and the improvement of quality of life
100 Clinical Results associated with Dendritic Killer Cell (DKC)(FullHope Biomedical)
100 Translational Medicine associated with Dendritic Killer Cell (DKC)(FullHope Biomedical)
100 Patents (Medical) associated with Dendritic Killer Cell (DKC)(FullHope Biomedical)
100 Deals associated with Dendritic Killer Cell (DKC)(FullHope Biomedical)